PTAB Invalidates Aventis Patent Following Mylan Challenge

Drug Industry Daily
A A
The PTO’s Patent Trial and Appeals Board invalidated Aventis Pharma’s patent for the chemotherapy drug Jevtana (cabazitaxel), following a challenge from Mylan.

To View This Article:

Login

Subscribe To Drug Industry Daily